Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of Vemurafenib Treatment Duration and Dosing in BRAF-Mutated Refractory Juvenile Histiocytic Proliferations
2020-005052-37Phase 2Active
- Sponsor
- Institute of Mother and Child
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vemurafenib in histiocytosis, Langerhans cell histiocytosis (LCH) and cancer, sponsored by Institute of Mother and Child. Primary endpoint: Event-free survival (EFS). Started Jan 2021; status: active.
02
Drugs
vemurafenib
03
Conditions
histiocytosisLangerhans cell histiocytosis (LCH)cancer
Beyond the preview
Go deeper on 2020-005052-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005052-37.